KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Investing Activities: 2018-2025

Historic Cash from Investing Activities for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $700.0 million.

  • Moderna's Cash from Investing Activities fell 2.91% to $700.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 25.38%. This contributed to the annual value of $1.9 billion for FY2024, which is 53.66% down from last year.
  • Latest data reveals that Moderna reported Cash from Investing Activities of $700.0 million as of Q3 2025, which was up 24.11% from $564.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Cash from Investing Activities peaked at $2.0 billion during Q1 2023, and registered a low of -$3.9 billion during Q1 2022.
  • Its 3-year average for Cash from Investing Activities is $740.8 million, with a median of $721.0 million in 2024.
  • Per our database at Business Quant, Moderna's Cash from Investing Activities crashed by 29,930.77% in 2021 and then soared by 518.64% in 2025.
  • Over the past 5 years, Moderna's Cash from Investing Activities (Quarterly) stood at -$1.1 billion in 2021, then grew by 7.91% to -$1.0 billion in 2022, then skyrocketed by 48.66% to -$538.0 million in 2023, then declined by 0.19% to -$539.0 million in 2024, then declined by 2.91% to $700.0 million in 2025.
  • Its Cash from Investing Activities was $700.0 million in Q3 2025, compared to $564.0 million in Q2 2025 and $730.0 million in Q1 2025.